Close Menu

KellBenx

The company's technology relies on detecting a fetal cell-specific antibody in order to isolate and analyze the cells as early as six weeks gestation.

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

NEW YORK (GenomeWeb News) – Looking to enter the fast-growing non-invasive prenatal diagnostics space, CellScape is eyeing a second-half 2014 commercial launch of its test, which detects for fetal aneuploidies, and more importantly, genetic disorders that currently require invasive methods for de

NEW YORK (GenomeWeb News) – Start-up KellBenX is positioning itself as the David among the Goliaths of the non-invasive prenatal diagnostics space by building a test that it said can detect fetal chromosomal abnormalities beyond aneuploidies.

KellBenx Raises $2.5M

Funds from the round will be used to conduct a clinical trial and build its laboratory.

The Long Island, NY-based company will use the three biomarkers to develop blood-based tests to predict premature births.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders."

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.